POLYNAUT
LIVE

Serial Number

99630692

Owner

VIANAUTIS BIO LIMITED

Attorney

Ben Natter

Filing Date

Feb 3, 2026

Add to watchlist:

No watchlists yet
View on USPTO

POLYNAUT Trademark

Serial Number: 99630692

POLYNAUT is a trademark filed by VIANAUTIS BIO LIMITED on February 3, 2026. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

VIANAUTIS BIO LIMITED (2 trademarks)

Pioneer House, Chivers Way, Histon,
Cambridge CB249NL , GB

Entity Type: 99

Trademark Details

Filing Date

February 3, 2026

Registration Date

Not Registered

Goods & Services

Chemicals used in science; chemicals for encapsulating, microencapsulating and decapsulating other chemicals; chemicals for the protection, delivery, transport and triggered or controlled release of other chemicals; chemicals for encapsulating, microencapsulating and decapsulating biologically active ingredients including enzymes and cells; reagents and diagnostic preparations for scientific or medical research use, and clinical or medical laboratory use; targeted diagnostic preparations for scientific or medical research use, and clinical or medical laboratory use

Scientific and technological services, namely, scientific research, analysis, testing and development in the field of delivering therapeutics, drug delivery technologies and medicines and research and design relating thereto; industrial analysis and research services in the field of therapeutics, drug delivery technologies and medicines; research and development in the field of encapsulating, microencapsulating and decapsulating chemicals and biologicals for delivery into human or animal cells; medical and veterinary research services; scientific research in the development of new therapies and new methods for delivering therapies; scientific research into nanoparticles; scientific research into encapsulation, microencapsulation and de-capsulation of reagents, diagnostics, prophylactics and therapeutics; scientific research into crossing the blood brain barrier and other biological barriers; scientific research into nano-engineering for intracellular delivery; platform as a service (PAAS) featuring computer software platforms for developing drug delivery products to deliver genetic materials with precise targeting of specific tissues and cell types; platform as a service (PAAS) featuring computer software platforms for research and development of genetic medicine delivery; consultancy relating to all the aforesaid services.

Pharmaceutical preparations; Pharmaceutical preparations for the treatment and prevention of infectious, autoimmune, viral, metabolic, musculoskeletal, cardiovascular, genitourinary, central nervous system, endocrinological, immunological, obstetrical, gynaecological, oncological, respiratory, neurological, gastrointestinal, hormonal, dermatological and psychiatric diseases and disorders; reagents, diagnostics, prophylactics and therapeutic preparations for use in conditions of the central and peripheral nervous systems, immune system and diseases of the lung, kidney, liver or any peripheral organs, and oncology; vaccines; therapeutic preparations for use in treating diseases of the central and peripheral nervous systems, immune system and diseases of lung, kidney, liver or other organs, and cancer in medical and veterinary patients; targeted preparations for treating diseases of the central and peripheral nervous systems, immune system and diseases of lung, kidney, liver or other organs, or cancer; medical and veterinary preparations for use in for use in central and peripheral nervous system diseases, immune system, diseases, diseases of the lung, kidney, liver and other organs, and cancer; medical and veterinary preparations for the delivery of compounds to the brain for the treatment and prevention of infectious, autoimmune, viral, metabolic, musculoskeletal, cardiovascular, genitourinary, central nervous system, endocrinological, immunological, obstetrical, gynaecological, oncological, respiratory, neurological, gastrointestinal, hormonal, dermatological and psychiatric diseases and disorders; medical and veterinary preparations for crossing the blood-brain barrier for the treatment and prevention of infectious, autoimmune, viral, metabolic, musculoskeletal, cardiovascular, genitourinary, central nervous system, endocrinological, immunological, obstetrical, gynaecological, oncological, respiratory, neurological, gastrointestinal, hormonal, dermatological and psychiatric diseases and disorders; medical and veterinary preparations for delivering reagents, diagnostics, prophylactics and therapeutics across the blood-brain barrier for the treatment and prevention of infectious, autoimmune, viral, metabolic, musculoskeletal, cardiovascular, genitourinary, central nervous system, endocrinological, immunological, obstetrical, gynaecological, oncological, respiratory, neurological, gastrointestinal, hormonal, dermatological and psychiatric diseases and disorders

Filing History

NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 5, 2026 GNRN
NON-FINAL ACTION E-MAILED
Jun 5, 2026 GNRT
NON-FINAL ACTION WRITTEN
Jun 5, 2026 CNRT
ASSIGNED TO EXAMINER
Jun 1, 2026 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 28, 2026 NWOS
APPLICATION FILING RECEIPT MAILED
Feb 3, 2026 MAFR
NEW APPLICATION ENTERED
Feb 3, 2026 NWAP